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GOOD ENOUGH TO USE FOR RESEARCH, BUT NOT
GOOD ENOUGH TO BENEFIT FROM THE RESULTS
OF THAT RESEARCH: ARE THE CLINICAL HIV
VACCINE TRIALS IN AFRICA UNJUST?
Ruqaiijah Yearby*

INTRODUCTION

The epidemic of the Human Immunodeficiency Virus (HIV) infec
tion in Sub-Saharan Africa,l the region most affected by the HIV pan
demic and where HIV is the leading cause of death, is reaching
insurmountable proportions. In fact, out of the 36.1 million HIV in
fections worldwide, 25.3 million, seventy percent, are in Sub-Saharan
Africa. 2 Additionally, of the more than 15.000 people who are in
fected with HIV every day, ninety-five percent of the cases are in
populations that live in developing countries such as those located in
Sub-Saharan Africa. 3 Due to the significant number of Africans in·
fected with HIV, many researchers and ethicists have focused their
attention on granting Africa fair opportunity to have access to clinical
HIV vaccine trials. But fair opportunity to participate in clinical HIV
vaccine trials does not guarantee that Africans will benefit from the
research because of the very nature of clinical trials.
Assistant Professor of Law, Loyola University Chicago School of Law. I am grateful to
John Blum, Roderick Nelson , Lawrence Singer, Neil Williams, and Ayanna Yearby for gener
ously sharing their insights a nd comments on this work and for suggesting opportunities for
future work. I would also lik" to thank my research assistants, Simone Ortuanya and Timothy
Rozoff, for their invaluable co ntributions and Elissa Koch for numerous thoughtful discussion s.
\-tany thanks to the symposium participants, particularly Michele Goodwin and the editors at the
DePaul Law Review , for putting together an excellent symposium that featured numerous valua
hI e contributions .

1. Sub-Saharan Africa includes all of the countries of Africa exce pt eight. The countries not
included in Sub-Saharan Africa are the Wes tern Sahara, Morocco. Algeria, Tunisia, Libya,
Egypt , Sud an, and J::ritr~a. See The Or. for HIV Info., Univ. of Cal. , San Francisco Sch. of Med.,
Sub -Saharan Africa Map (2003), at http://hivinsite.ucsf.edu (last visited Feb. 4, 2004).
2. See A Difference of 15 Years, WASH. POS1, July 4, 2000, at http://www.washingtonpost.comJ
wp-srv/world/daily/julyOO/aidsgraphic.htm (las t visited Feb. 4, 2004).
3. See Jose Esparza, An HIV Vaccine: How and When? , 79 BULL. WORLD HEALTH ORO. 1133
(2001); BARNEY S. GRAHAM, NATIONA L INSTITUTES OF H EA LTH V ACCINE R ESEARCH CENTER
REPORT, CLINICAL TRIALS OF HIV VACC INES 2 (2001).
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A clinical trial consists of a research study that uses human subjects
to evaluate the efficacy of new drugs and treatments.4 The purpose of
clinical trials is to develop new treatments to prevent or treat dis
eases. S Although trials offer the prospect of benefits for the individu
als participating in the tri als, in reality, many subjects do not receive a
net benefit because the new drugs and treatments have unknown side
effects and dangers.6 Rather, the benefit is to society.7 In an attempt
to protect the lives of individuals participating in these trials, the
United States and other nations developed ethical principles applica
ble to clinical trials. The three fundamental ethical principles are: 8
Respect of Persons,9 Beneficence,lO and Justice. These ethical princi
ples prevent the manipulation and exploitation of research subjects
for the benefit of society as a whole. Furthermore, these principles
provide the framework for researchers in the United States and
abroad regarding what is humane and what the acceptable risk is for
research subj ects to bear. l l In the U nited States, these principles have
been codified and are therefore compulsory.12 Abroad, these princi
ples are widely accepted and appear in documents of international
ethical principles.13 Of these ethical principles, this Article will focus
on the Justice principle and its application to clinical trials.
4. TOM BEA UCHA MP & J AM ES CH ILD RESS, PR INCIPLES OF BIOMEDICAL ETHICS 441 (4th ed.
1994).
5. ld.
6. ld.
7. Id .
8. Th ese three princi ple; are found in th e Belm ont Report: Ethical Principles and Guidelines
for th e Protection of Human Subjects of Riom edical and Behavioral Research. See The Be lm ont
Report, 44 Fed. Reg. 23,192, 23,1 94 (A pr. 18, 1979). This docum ent was dra fte d by the National
Commission for the Protection of Human Subj ects of Biomedical and Behavioral Research in
1976 and published in the Federal Registe r. ld.
9. Th e doct rin e of R espect of Persons includes two main e thical canons: autonomy and pro.
tection. Researchers must treat human research subjects as auto nomous agents and provide
protections for those with diminished a utonomy. ld . at 23,193.
10. Bene fict:l1ce requires researchers to "not only respect the autono my of the research su b·
jects but also make an effort to secure their well·being." ld. at 23,194.
11. ld. 111is is important because most of the countries in which the Unit ed States is fund ing
and conductin g clinical trial s do not have effecti ve mechanisms available to review the ethical
implicati ons of the research . See UNA ID S Rep ort: UNA IDS Sponsored Regional Workshops To
Discuss Eth ical Issues in Preventive H1 V Vaccine Trial;~ U .N. Progamme on HIV and A IDS
(U NAIDS) , at 8, U NAIDS Doc. 00 036 (2002).
12. 45 C. F.R. § 46.101 (2003 ).
13. In fact the principle of Justice was found only in the Belmont Report until 2000, wh en the
World Medical A ssocia tio n added the principle to th e Declaration of Helsinki , a renowned docu·
ment of bioethics for clinical trials. The Belmont R eport, 44 Fed. Reg. at 23,1 92; see also WORLD
MED. ASS'N, THE D ECLARATION OF H ELSI NKI (2002), available at http://www.wma.net/e/policy/
b3.htm (last visited Feb. 4, 2004) .
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The expansive doctrine of Justice encompasses the principles of
fairness, equity, and equality.1 4 This broad doctrine of Justice has a
limited application to clinical trials in that it demands that the "soci
ety" that benefits from the results of the study must include individu
als similar to those who participate in the study.15 In this context,
Justice addresses issues of a population's right to be treated equally,
while Respect of Persons and Beneficence address the rights of an
individual. Even though statements of Justice can be found in the eth
ical guidelines of most countries and medical organizations,16 this Ar
ticle will focus on the statement of Justice found in two of the most
renowned statements of ethics: the United States's The Belmont Re
port: Ethical Principles and Guidelines for the Protection of Human
Subjects of Research (Belmont Report) and the World Medical Asso
ciation's Declaration of HelsinkiY As this Article will show, however,
some researchers have perverted the principle by consistently ignoring
the requirements of Justice when conducting research in developing
countries or regions such as Sub-Saharan Africa. 18 Individuals who
participate in clinical trials in Africa bear the same burden that Amer
ican research subjects bear but do not receive the same benefits.
Thus, one must ask why Africans are good enough to use for medical
research but not good enough to be included in the "society" that ben
efits from that research.
Illustrative examples of this problem are the clinical trials con
ducted by some American researchers to prevent the spread of HIV in
Sub-Saharan Africa. In the late 1990s, researchers from the United
States traveled to Sub-Saharan Africa and conducted drug trials. 19
Many of these trials involved testing the effectiveness of new treat
ments and developing a shorter length of treatment for drugs already
in use to prevent mother-to-child HIV transmission.20 Unfortunately,
because of the astronomical cost of these new treatments and drugs,
14. The Belmont Report, 44 Fed. Reg. at 23,196; see also WORLD M ED . ASS'N, supra note 13.
15. The Belmont Report , 44 Fed. Reg. at 23,1 96; see also WO RLD MED. ASS'N, supra note 13.
16. Recently, many countries, such as the United Kingdom, Canada, Nepal, Uganda, and Bra
zil, have revised their ethical guidelines to address access to post-trial benefits. See Alice Page,
Prior Agreements in International Clinical Trials: Ensuring Ih e B enefits of Research to Developing
Co untries, 3 YAI L J. H EA LTH PO L' y, L. & E T H[CS 35, 50 (2002). Neve rtheless. many of the
guidelines are not compulsory and have no enforcement mechanism. Id.
17. The Belmont Report, 44 Fed. Reg. at 23,194; see also WORLD ME l). ASS'N, supra note 13.
18. For example, researchers conducting AZT drug trial·. in Africa to prevent mother-lo-child
transmi ssion offered some subjects placebos even though the same trials conducted in the
United Stales provided each subject with dru gs. Id. For more discussion , see infra subpart
II(B) .
19. David Studdert & Troyen Brennan. Clinical Trials in Developing Countries: Scientific and
Ethical Issues, 169 M E l) . J. AUSTL. 545 (1998).
20. Id.
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few Sub-Saharan African countries and citizens would have had access
to these treatments and drugS. 21 Therefore, relatively few Africans
afflicted with HIV directly benefited from the results of this re
search. 22 Many researchers and ethicists questioned why Africans
should bear the burden of participating in the research when they did
not benefit from the results of the studies. 23 In response to these
questions, researchers asserted that exorbitant costs meant that "soci
ety" should only include those who could afford treatment once it was
patented and packaged by corporations. 24 Moreover, some research
ers argued that Justice applies to an individual's right to participate in
clinical trials. 2s But who does the Justice principle protecting-indi
viduals or populations?
In the case of the HIV drug trials, leading ethicists asserted that
neither individual Africans nor the African population benefited from
these trials. As a result of these problems and negative publicity,
many of these studies were terminated before completion or the struc
ture of the trials was changed because of the violations of individual
and population rights. Nevertheless, neither research~rs nor ethicists
reached any consensus regarding the requirements of the Justice prin
ciple in clinical trials conducted in Africa and other developing coun
tries.26 Questions of who is included in the "society" that henefits
from a particular study and whether the Justice principle may be lim
ited by concerns related to cost are paramount issues that persist and
need answering as researchers commence HIV vaccine trials in Africa .
The first HIV vaccine trial was conducted in Africa in 1987 by a
French doctor who immunized himself and a small group of Zairians

21. Ronald B ayer. The Debate over Maternal·Fetal HIV Transmission Prevention Trials in / IF
rica, Asia, and the Caribbean: Racist Exploitation or Exploitation of Racism?, 88 AV!. J. Pen.
HEALTH 567, 570 (1998).

22. [d.
23. Georgt: Annas & Michael Grodin , Human Rights and Waternal-I:etal HIV Transmission
Prevention Trials in Africa, 88 AM. J. PU B. H EALTH 560, 560-61 (1998); R.A . Cro uch & J.D.
Arras, A7T Trials and Tribulations, 28 H ASTINGS C ENTI.R REP. 26, 29 (1998); L.H. G lantz, Re
search in Developing Countries: Taking Benefit Seriously, 28 H ASTINGS CENTER R EP. 38, 40-42
(1998); Marcia Angell, The Ethics of Clin ical Research in the Th ird World. 337 N EW ENG . J .
MED. 847, 847-48 (1997).
24. See Pett:r Luri e & Sidney Wolfe, Unethical Trials of Interven tions To Red/lce Perinatal
Transmission of Human Immunodeficiency Virus in Developing Countries, 337 ~, \V r "" ,. 1.
MED. 853, 854-55 (1997).
25. Harold Varmus & D avid Satcher, Ethical Complexities of Condu('ring i<esearch in Devel
oping Countries, 337 NEW ENG. 1. MED. 1003,1 004 (1997).
26. Studdert & Brennan, supra note 19, at 545.
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with an investigational HIV vaccine.27 According to a New York
Times article published at the time, the reason the study was con
ducted in Zaire was because "it was easier to get official permission
[in Zaire] than in France,"?8 not because the population would benefit
from the trials. 29 Since that trial, only four other HIV vaccine trials
have been conducted in Africa, three of which began in 2003. 30 The
trials currently being conducted in Africa, unlike the drug trials in the
late 1990s and the first HIV vaccine trial, are not inherently discrimi
natory in their practice. However, it is questionable whether Africans
will benefit from these trials because, in part, researchers have not
guaranteed Africans access to the HIV vaccine if it proves effective.
In the past, the Belmont Report and the Declaration of Helsinki
would provide the framework to address this problem; however, now
some of the HIV vaccine trials are funded by private industry and are
exempt from these requirements. 31 For instance, the International
AIDS Vaccine Initiative (IAVI), an international scientific organiza
tion, funds the HIV vaccine trial conducted in Uganda. 32 Neither the
Belmont Report, which only applies to research funded by the U.S.
government,33 nor the Declaration of Helsinki, which applies to all in
ternational trials but is only advisory,34 applies to that trial. Some
scholars have suggested requiring researchers and funders to enter
into prior agreements with individual countries to negotiate the pro
posed benefits before the research begins; however, these agreements
27. The Zairians tested we re HIV-negative before receiving the vaccine. Nicholas A. Chris
takis, The Elhical D esign of an AIDS Vaccine Trial in Africa, 18 HA STINGS CENTER R EP. 31 , 31
(1988).
28. Z aire, Ending Secrecy, Auacks AIDS Openly, N.Y. TIMES, Feb. 18, 1987, at AI, cited in
Christakis, supra note 27, at 3l.
29. In an a rticle published in the Na ture journal, Dr. Daniel Zag ury claims that he not only
had the full support of the Zairian government but also worked with a group of Zairian scientists
o n th(; project. {d. Dr. Zagury used this to justify the vaccin e trial; howeve r, human research
guidelines o f the World Health Organization and the Council for Int<.! rnationa l Organizations o f
Medical Scie nces required th a t the ett,ical standards, which are applied to research studies con
ducted in the resea rche r's o wn country, must also be applied to research studies conducted in
developing cou ntries. Christakis, supra note 27, at 3l.
30. See Roy Mu gerwa et aI. , First Trial of the HIV-J Vaccine in AJi'iea: Ugandan Experience,
324 BRITISH M ED. J. 226, 228 (2003); NAT'L INST. OF H EALTH , SAFETY OF AN HIV VACC INE
(AVX101) IN HIV UNI NFECTED VOLUNTEERS IN THE UNITED STATES AND SO UTH A FRI CA
(2003) , available at http://www.c1inicaltrials .gov (last visite d Feb. 4, 2004); NAT' L INST. OF
H EALTH , S AFETY Of AND IMM UNE SYSTEM R ESPONSE TO AN HIV VACCINE (EP HIV-1090) IN
HIV UN INFECTE D A DULTS (2003), available at http://www.clinicaltrials.gov (last visited Feb. 4,
2004).
31. Richard R ettig, Th e Industrialization of Clinical R esearch, H hALTH Aff., Apr.-May 2000,
at 129, 131.
32. Mugerwa et aI., supra note 30, at 228.
33. 4S c.F.R. § 46.101 (2003) .
34 . WOR LD M ED. ASS'N, supra note 13.
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are not compulsory and provide no additional mechanism of enforce
ment beyond the advisory requirement of the Declaration of Hel
sinki. 35 The best way to ensure that the African populations that bear
the burden receive a benefit is to draft and implement a compulsory
international document of ethical protections enforced by an interna
tional organization.
This Article explores the ethical principle of Justice and its applica
tion to clinical trials in developing countries through the lens of the
current HIV vaccine trials in Sub-Saharan Africa. Part II examines
the history of the Justice principle as it pertains to clinical trials and
answers the question of who should be included in the "society" that
benefits from the results of the research. The benefits of the Justice
principle, fair access to the results of clinical trials, are compared to
the benefits of fair opportunity to clinical trials in Part III, which re
views the problems with past clinical HIV drug trials conducted in
Sub-Saharan Africa. Part IV briefly surveys the current HIV vaccine
trials underway in Africa, discusses some of the failures of researchers
to apply the principle of Justice, and suggests a possible mechanism to
ensure that fu ture clinical trials conducted in Africa provide a benefit
to a "society" that includes Africans.
II.

T HE HISTORY OF THE JUSTICE PRINC IPLE AND

ITs

ApPLICATION TO CLINICAL TRIALS

The Justice principle encompasses fairness and equity.36 Norman
Daniels, a Professor of Ethics at the Harvard School of Public Health,
states that Justice requires everyone be given a fair opportunity to
resources including health careY Aristotle defined Justice in terms of
equality: equals must be treated equally and unequals must be treated
unequaUy.38 The French philosopher, Rosseau, said that because all
men are born equal one must "treat all men [and women] with com
plete equality and justice will prevail."39 But how is Justice achieved?
The principle of Justice is an active process used to remedy or prevent
what would arouse a sense of injustice. 40 These same general princi
ples of Justice are applied to protections of human subjects participat
ing in clinical trials. There are two main documents that govern
35.
36.
37.
38.
39.

Page, supra note 16, at 38-43 .
The B elmont R eport , 44 Fed. Reg. 23,192. 23,194 (Apr. 18. 1979).
NORM AN D ANI ELS, JUST H EALTH CARE 34-58 (1985).
B EAUCHA MP & CHILDRESS. supra not e 4, at 328.
JE AN-JACQU ES ROUSSEAU, TH E SOCIAL CONTRACT 4 (Maurice r:ranston trans. , Penguin
B ook s 1968) (1762).
40. EDWARD CAH N, TH E SENSE OF JU STICE 14-15 (1949).
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international clinical trials and espouse the requirements of Justice:
the Belmont Report and the Declaration of Helsinki. 41 According to
these documents, Justice requires that populations used for research
be treated equally and fairly.42 As a review of these documents
shows, the application of this principle to clinical trials has a long, sor
did history-internationally and in the United States.
The first discussion concerning the allocation of burdens and bene
fits of clinical trials appeared in the United States's Belmont Report. 43
In the early 1970s, the U.S. Senate Committee on Labor and Human
Resources held hearings on some of America's most egregious clinical
trials, such as the Tuskegee Syphilis Study conducted from 1932
through 1972, in which poor African-American men were denied ac
cess to standard treatment. 44 As a result of the hearings, Congress
enacted the National Research Act of 1974, which required the U.S.
Department of Health, Education, and Welfare (HEW)45 to develop
and publish policies for the protection of human subj ects in the Code
of Federal Regulations. 46 In addition, Congress created the National
Commission for the Protection of Human Subjects of Biomedical and
Behavioral Research (Commission)47 and imposed a moratorium on
41. The precursor to international ethical protections or human subjects participa ting in
clinical tria ls was the Nuremberg Codl! (Code) in 1947. which was developed in response to the
Trials of War Criminals before the Nuremberg Military Tribunals. See NU REM BERG CODE
(1947) , available at http://ohsr.od.nih.gov/nuremberg.php3 (last visited Feb. 4, 2004). The Code
does not explicitly discuss the equal distrihution of burdens and benefits from the results of
clin ical trials; however, the Code notes that experiments should yield fruitful results for the good
of society. Although this statement does not directly address who is included in society, it served
as the building block of the Justice principle defined in the Belmont Report. See The Belmont
Report, 44 Fed. Reg. at 23,1 92.
42. TIle Belmont Report, 44 Fed. Reg. at 23 ,192.
43 . [d.

44. See gen.erally JAME S H. JONES, BAD BLOOD: TJ-IL TUSKEGEE SYPHILIS E XPERIM ENT
(1981).
45 . The U .S. Department of Health, Education, and Welfare was renamed the U. S. Depart
ment of Health and Human Services in 1980. See Department of Education Organization Act,
Pub. L. No. 96-88, § 509(e), 93 Stat. 6Y5 (1979) (codified at 20 U.S.c. § 3508 (2000».
46. See National Research Act of 1974, 42 U.S.c. § 2891 (2000).
47. The Commission wa:; composed of eleven members appointed by the Secretary of HEW.
The National Research Act advised the Secretary of HEW to choose the members of the Com
mission from distinguished individuals from the fields of medicine, law, ethics, theology, philoso
phy, humanities, health administration, government, public affairs, and the biological, physical,
behavioral, and social sciences. ld. Five of the members of the Commission had to be individu
als e ngaged in biomedical or behavioral research involving human subjects. ld. Members o f the
Commission included Dorothy 1. Height, President of the National Council of Negro Women,
Inc .. Dr. Albert R. Jonsen, Professor Emeritus of Medical History and Ethics at the U nive rsity
of Washington, and Patricia King, the Carmack Waterhouse Professor of Law, Medicine, E thics,
and Public Policy at Georgetown University Law Center. See The Belmont R eport, 44 Fed . Reg.
at 23,192.
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research conducted or supported by HEW until adequate protections
for research subjects were developed. 48
The duties of the Commission were to identify the basic ethical
principles that should govern medical and behavioral research involv
ing human subjects, advise the Secretary of HEW on what changes to
make to HEW policies governing clinical trials, and draft final guide
lines that would ensure that researchers conducted clinical trials in
accordance with these ethical principles. 49 To achieve this end, the
Commission reviewed the existing HEW framework, recommended
changes to the Secretary of HEW, and revised HEW's policy pertain
ing to clinical trials in the Belmont Report. 5o The Belmont Report
was an outgrowth of the Commission's deliberations regarding ethical
protections at monthly meetings and a 1976 conference at the Smith
sonian Institute's Belmont Conference Center. 51 In 1979, the Bel
mont Report was published in the Federal Register as the official
policy statement of basic ethical principles and guidelines of HEW re
garding research with human subjects.52 In the Belmont Report, the
Commission selected Justice as one of the three fundamental ethical
principles 53 and defined Justice by first asking the question: "Who
ought to receive the benefits of research and bear its burdens?"54 To
answer this question and establish the contours of Justice, the Com
mission defined what is just and what is unjust.
According to the Commission, an injustice occurs during clinical tri
als when a benefit is denied to a person without gooJ reason or a
burden is unduly imposed on a person, "whereas Justice requires that
equals be treated equally. "55 In the context of clinical trials, the Bel
mont Report states:
Whenever research supported by public funds leads to the develop
ment of therapeutic devices and procedures, justice demands both
that these not provide advantages only to those who can afford
48. 42 u.s.c. § 289l.
49. ld.
50. The Commission issued several reports tha t addressed the need for ethical protections and
a summary of their monthly meetings; however, the Be lmont Report was their final statement of
ethical principles that govern medical and behavioral research. See NAT'L i NST. OF H EALTH,
GUIDELINES FOR THE CONDUCT OF RESEARGi INVOLVIN G H UMA1< SUBJ ECTS AT TH E NATIONAL
hSTfTLTES OF HEALTH (1995), available at http://ohsr.od.nih.gov/guidelines.php3 (last visit ed
Feb. 4, 2004). After drafting the Belmont Report , the Commission was dissolved in 1978. Id.
5l. ld.
52. In J 979, HEW began revising its policies regarding clinical trials. The revisions becam e
fi nal in 1981. See The Belmont Report , 44 Fed. Reg . a t 23,192.
53. The two other principles wen; Respect for Persons and Beneficence. For a definition of
each of these ethical principles, see supra notes 9 and 10.
54. ld. at 23,194 .
55. ld.
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them and that such research should not unduly in volve persons from
groups unlikely to be among the beneficiaries of subsequent applica
tions of the research. 56

Thus, Justice prevents one population or group from being used for
research without a benefit, while other populations or groups not used
for research receive a benefit. The Commission's statement of Justice
evolved from its view of the historical use of many vulnerable and
disadvantaged populations for research that lead to the exploitation of
these populations for the good of society.57 Furthermore, the Com
mission specifically mentioned the need to apply the Justice principle
to clinical trials to prevent other atrocities, such as those committed in
the Tuskegee Syphilis Study and in the Nazi concentration camps.58
Thereafter, the Commission applied this definition to evaluate who
should bear the burden and receive the benefits of clinical research.
To protect human subjects in clinical trials, the Commission deter
mined that when research subjects are selected, "the principle of jus
tice gives rise to moral requirements that there be fair procedures and
outcomes in the selection of research subjects. "59 Justice requires
that the selection of human subjects for clinical trials be scrutinized to
ensure that the population is not selected merely because research
subjects are easily available, in a compromised position, or readily
manipulated. 60 Moreover, in government-funded clinical trials to de
velop drugs and vaccines in the United States and abroad , Justice dic
tates that subjects from vulnerable populations receive a benefit from
the resul ts of the trials. 61
The Belmont Report 's iteration of the Justice principle was codified
in 1986 in the Code of Federal Regulations.62 Initially the principle
was only applicable to research conducted and funded by HEW, but
in June 1991 , the Belmont Report was changed to govern all federally
funded research.o3 Today, before U.S. scientists conduct government
funded clinical trials in the United States and abroad, the researcher
must comply with the above-mentioned requirements of the Justice
principle. 64 The problem with the Belmont Report is that it only ap
56_ l d. (e mph asis added).
57. The Com mission noted the relevance of Justice because of the egregious ethical viola tions
commi tted in the Tus kegee Syphilis Study and in th e Nazi concentra tion camps. ld_
58. NAT' L INST. OF HEALTH, supra note 50.
59. Th e Belmo nt Report, 44 Fed. Reg. at 23,192.
60 _ l d, at 23,1 94_
61. ld . at 23,197_
62_ NAT' L INST, OF H EALTH, supra nute 50.
63_ 56 Fed_ R eg, 28,003, 28,003 (June 18, 1991) ,
64 , Before U .S, researche rs begin clinical trials, they mus t submit a written assurance to the
appro pri ate Instituti o nal Review Boa rd (IRB )- 45 C,ER. § 46.101(a )(2) (2002)_ A co mplete
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plies to trials conducted or funded by the United States. 65 Trials
funded by private industry do not have to comply with the Belmont
Report's protections. These trials would be governed by international
law, such as the Declaration of Helsinki, which includes some of the
same ethical principles featured in the Belmont Report.
The Declaration of Helsinki, drafted and adopted in 1964 by the
World Medical Association, is a statement of ethical standards that
was designed as a guide to physicians and others participating in medi
cal research involving human subjects, in addition to the responsibili
ties imposed by their own countries.66 In 2000, thirty-six years after
the adoption of the document,67 the World Medical Association
amended the Declaration of Helsinki to include the Justice principle. 68
The impetus of this revision was a proposal submitted by the Ameri
can Medical Association (AMA) in 1997, which significantly revised
the Declaration of Helsinki. 69 The AMA's revisions were issued as a
World Medical Association document and discussed at the World
Medical Council's 153rd Session in Santiago, Chile in April 1999.70
The revisions submitted produced considerable debate and contro
versy because they addressed the use of placebos in research and the
standard of care ethically required for subjects participating in clinical
trials in developing countries. 7! After debating the revisions at con
ferences, symposiums, and workshops, the World Medical Association
adopted the revisions on October 7, 2000, making it the first interna
written assurance includes a statement of the ethical principles protecting the rights and welfare
of human research subj ects based on the ethical principles of the Belmont Report. 45 CF.R.
§ 46.103(b)(I) (2002). An IRB, a board found in all kderal agencies and universities that con
duct biomedical research, reviews all written assurances in application for clinical trials. See 10
CF.R. § 745.101 (1991); 28 c.F.R. § 46.101 (1991); 45 C.F.R. § 46.109 (2002). The IRR reviews
the proposal to ensure that the propose d trials are ethical and has the authority to "approve,
require modifications in (to secure approval), or disapprove" any application. 45 C.F.R.
§ 46.109(a) .
65. 45 C.F.R. § 46.10l.
66. Research governed by the D eclaration of Helsinki includes research involving identifiable
human material or data . See WORLD M ED. ASS'N, supra note 13.
67. The 2000 revision of the D eclaration of Helsinki was the fifth revision to the document.
Id. The document was revised in 1975, 1983, 1989, 1996, 2000, and 2002. Id.
68. The latest version of the D eclaration of Helsinki was published in 2002; howeveI. the prin
ciple of Justice fir st appeared in the Declaration of Helsink i in 2000. The World Medical As:;oci 
ation amended the Declaration of Helsinki at the 52nd World Medical Association General
Assembly Meeting in Edinburgh, Scotland in October 2000. The World Medical Association in
Washington added a note of clarification in 2002, but this revision Jid ;lOt affect the statemen t of
the Justice principle. Id.
69. Delon Human & Sev S. Fluss, Th e World Medical Association's D eclaration of Helsinki:
Historical and COl1lemporary Perspective 1, 13-15 (2001) , at http://www.wma .net/e/ethicsunit/hei
sinki.htm (last visited Nov. 17, 2003).
70. Id . at 13.
71. Id. at 15.
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tional ethical document to recognize the Belmont Report's Justice
requirement. 72
Comparable to the Belmont Report, the Declaration of Helsinki ad
vises medical researchers that clinical trials are only just if the popula
tion used for research benefits. The Declaration of Helsinki states:
"[M]edical research is only justified if there is a reasonable likelihood
that the populations in which the research is carried out stand to bene
fit from the results of the research. "73 Hence, the Justice principle
should be used by researchers in evaluating who should participate in
clinical trials by first identifying those populations that will benefit
from the results of the trials. 74 If the population will not benefit from
the results of the research, then the researcher must choose subjects
from another population. 75 The incorporation of the Justice principle
into one of the premier international documents regarding human
rights and clinical trials demonstrates clearly the importance of the
principle in protecting research subjects across the world . Unfortu
nately, the Declaration of Helsinki is not compulsory.
Nevertheless, Professors Francis Crawley and Joseph Hoet describe
the Declaration of Helsinki as "the cornerstone of biomedical research
for the last 30 years [and] the largely unquestioned anchor for ethical
decision-making in clinical trials. "76 Moreover, many medical jour
nals, such as the New England Journal of Medicine, require that re
searchers publishing articles concerning clinical trials meet the ethical
requirements of the Declaration of Helsinki.7 7 In May 2002, the
United Nations Programme on HIV and AIDS (UNAIDS) included
the Justice principle from the Declaration of Helsinki in its guidance
document, Ethical Considerations in HIV Preventive Vaccine Research,
which is now being used by researchers and foreign governments in
structuring clinical HIV vaccine trials in developinG countries.?/; Al
though many researchers acknowledge the significance of the ethical
protections in the Declaration of Helsinki and the Belmont Report,
some researchers continue to disregard the Justice requirement dis
cussed in these documents and use Africans to bear the burden and
72. [d. at 16.
73. WORLD MED . ASS'N, supra note 13.
74. Id. : see also The Belmont R"port. 44 Fed. Reg. 23,192, 23,197 (Apr. 18, 1979).
75. The Delmont Report, 44 Fed. Reg. at 23,196.
76. Francis Crawley & Joseph Hoet, Fthics and Law: 1 he Declaration of Helsinki Under Dis
cussion, 150 BULL. Mu). En-llcs 9, 10 (1999).
77. Marcia Angell, Erhical Imperialism ? Erhics in international Collaborative Clinical Re
search, 319 NE W ENG. J. MED. 1081, 1082-83 (1988).
78. UNA IDS, Ethical Considerations in HIV Pre ventive Vaccine Research (2002), at http://
www.unaids.org (last visited Feb. 4, 2004).
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risk of the research, while giving the benefit of the results of the re
search only to citizens of developed countries. 79 This was the case in
the now defunct HIV drug trials conducted in Africa in the 1990s. 80
III.

A.

HIV DRUG TRIALS

IN

AFRICA

Brief History of AZT Clinical Drug Trials in the United States
and in Africa

In February 1994, the AIDS Clinical Trials Group Study 076 (Study
076) was concluded in the United States. 81 Study 076 showed that
orally administering the drug Azidothymidine (AZT) to HIV-positive
pregnant women in the second trimester of pregnancy, intravenously
during labor, and orally to newborns upon birth reduced perinatal
transmission of HIV by two-thirds. 82 This regimen of AZT cost $800
per patient in U.S. dollars.S3 The expense of this regimen limited the
accessibility of this treatment, so researchers began to search for a
shorter, less expensive version of this AZT regimen, hut they were
uncertain about what research design method to use to test this new
regimen. In June 1994, the World Health Organization 84 convened a
group, which included no ethicists, in Geneva, and in an unpublished
report, the group concluded that replicating Study 076 was neither ec
onomically nor structurally feasible in developing countries. 85 In
stead, they concluded: "[P]lacebo-controlled trials offered the best
option for a rapid and scientifically valid assessment of alternative an
tiretroviral drug regimens to prevent [perinatal] transmission of HIV
[in developing countries]."86
Documents from the Centers for Disease Control and Prevention
(CDC) after the Geneva meeting show that eighteen clinical trials
studying interventions to prevent perinatal HIV transmission were in i
tiated. 87 These trials tested a variety of interventions to prevent per
79. Varmus & Satcher, supra note 25, at 1004. Studdert & Brennan, supra note 19. at 546·48.
80. A nnas & Grodin, supra note 23, at 560-6l.
81. /d.; Bayer, supra note 21 , at 567.
82. Perinatal transmission of HIV is when an HI V-positive pregnant woman gives the di se ase
to her newborn child. Annas & Grodin, supra note 23, at 560-61.
83. Baye r, supra note 21, at 570; Varmus & Satcher, supra note 25, at 1004.
84. The World Health Organization (WHO) is the health organization 01 th~ United N ations.
See http://www.who.int/country/en (last visited Feb. 4, 2004). All countries that are memb ers of
the U nited Nations may become members of WHO by accepting its constitution. Id. The
U nited States is a member of WHO. Id.
85. Bayer, supra note 21, at 570; see also Lurie & Wolfe, supra note 24, at 854.
86. R esearchers used this unpublished document to justify th eir u:;e of placebus in subseq uent
AZT drug trials in developing countries instead of providing th e long treatment of A7T th at was
give n to American research su bjects. Luri e & Wolfe, supra note 24, at 854.
87. Jd.
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The resea rchGrs conducting trials in Africa failed to provide AZT to
all the subjects. 9R Instead of giving African subjects the longer treat
ment of AZT that U.S. subjects were given, researchers gave pregnant
African women participating in the study placebos, even though it is
widely accepted that placebos cannot be used if a known treatment is
available.99 Because of the use of placebos, it was estimated that 1,000
babies contracted HIV.IOO In addition to this reprehensible act, the
benefits of these clinical trials were not fairly or equita bly distributed
between the U.S. and African populations used for the clinical trials.

B.

Who Benefited from the AZT Drug Trials Conducted in Africa?

The societal benefit from the AZT drug trials was gaining access to
a shorter-length treatment of AZT that prevented perinatal HIV
transmission. In this case, access to this drug was determined by the
cost of the treatment. The CDC estimated that the cost of the shorte r
length treatment of AZT was fifty dollars per patient, plus an addi
tional ten dollars per patient charge for the initial HIV test to de ter
mine who was infected.l°1 The cost of sixty dollars per patient for the
short treatment of AZT made the drug accessible to most A mericans
with or without health insurance.l°2 In the 1990s, the United States
spent approximately $3,000 per patienPOJ However, the shorter
length treatment of AZT tested in the clinical trials conducted in Af
rica was not financially feasible to the citizens of Africa and other
developing countries. In the 1990s, when the majority of these trials
were conducted , the amount spent on healthcare per patient in U .S.
dollars in each African country was well below SIxty dollars per pa
tient, as evidenced by Table 1.

98 . l d.
99. See BEAUCHAMP & CHI LDRESS, supra note 4, at 451 ; Lurie & Wolfe, supra no te 24, at 854
55; A nge ll , supra note 77, at 1082. The wi thholding of AZT was especially egregious because th e
manufacturer of A ZT usually made the drug ava ilable free of charge for use in clinical trials.
Lurie & Wo lfe, supra note 24, at R55.
100. Dyckm an , supra note 92, at 93 .
101. Anna s & G rodin , sup ra note 23, at 563.
102. l d.
103. The amo un t spent per patie nt in the United States jumped to ~4,178 in 1998. See OFFICE
OF TH E ACTUA RY, CTRS. FOR MEDICARE & MEDICAID SERVS., TABLE 1: NATIONAL H EALTH
E XPENDITUR ES AND SELECTED E CONOM IC INDI CATORS , LEVELS AND A VERA GE ANNU AL PER
CENT CHANGE: SELECTED CALENDA R YEA RS 1980-2012 (2003 ), available at http://cms.hhs.gov/
sta tistics/nhe/projections-2002/tl (last visited Feb. 4, 2004) .
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TABLE 1
H ealth Care Expenditures of African Countries Involved in
Perinatal HIV Transmission Prevention Trials 104

Country (Year)
Burkina Faso (1992)
Cote d' Ivoire (1995)
E thiopia (1990)
Kenya (1992)
Malawi (1990)
Tanzania (1 990)
U ganda (1994)
Zi mbabwe (1991)

Amount spent per patient (U.S. dollars)
22
22
5
13
11
5
10

86

The countries listed in Table 1 were sites of the clinical A ZT drug
tria ls. Based on the numbers in Table 1, seven out of eight of these
countries would not have been able to afford the sixty dollars per pa
tient necessary to purchase and provide the short-length A ZT treat
ment to infected pregnant women, unless they significantly increased
health care spending. 105 As a result of the short-length A ZT trials
conducted in Africa and other developing countries, these drugs were
marke ted and available to U.S. residents but not Africans.l06 Based
on the amount spent per patient per year, clearly these African coun
tries did not have access to the short-length treatment of A ZT after
the drug trials. Thus, the society that benefited most fro m the results
of these trials only included populations from developed countries
such as the United States. Many researchers and ethicists questioned
whether these studies were just, because the African population did
not benefit from the results of the African trials while the U.S. popu
lation did benefit.

C.

Justice or Fair Access?: The Debate over A ZT Drug Trials
Cunducted in Africa

Leading ethicists, physicians, and researchers on both sides of the
debate wrote articles addressing the ramifications of applying differ
104. Table reprinted from Annas & Grodin, supra note 23, at 564.
105. Many researche rs could argue that any African country could decide to spend more per
patient each year to purchase the drug. This discussion is important because it addresses the
need of countries to prioritize the use of their resources for the good of their citizens. However,
th e deci sions of African countries to spend an amount uf money on uther things besides health
spend ing is beyond the ~,cope of this Article and still does not preclude researchers' respon sibil
ity to use a population that will benefit from the results of the research. If a drug is estimated to
cost more than wha t is nurmally spent per year per patient the question is: Without a change in
spending, will the population benefit from the research?
106. Lurie & Wolfe, supra note 24. at 854-55.
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ent standards of Justice in AZT drug trials conducted in the United
States and in Africa.107 One critic of the trials , Dr. Marcia Angell ,
wrote in an editorial, "Human subjects in any part of the world should
be protected by an irreducible set of ethical standards .... "108 Other
wise, acceptance of this "ethical relativism" could result in widespread
exploitation of vulnerable populations in developing countries partici
pating in clinical trials. lo9 Researchers who conducted the short
length AZT trials in Africa argued that the lack of money dedicated
to paying for healthcare for Africans negated their duty to provide
Africans access to the results of the trial: a shorter-length AZT treat
ment. 11 0 Therefore, because of cost limitations, researchers argued
they should not be required to ensure ~hat thc populations used for
the study actually benefited from the results.1l1 However, these asser
tions show a patent misunderstanding of the Justice principle and its
application.
The statement of Justice in the Belmont Report demands, not ad
vises, that populations not be unduly burdened with research that is
unlikely to benefit them without mention of cosL1J2 According to the
Belmont Report, Justice is used to evaluate what population should be
used for research before the clinical trial is commenced to protect vul
nerable populations from exploitation. 1l3 Before research is con
ducted, federal funding agencies, researchers, and drug companies
must evaluate whether the population being used as subjects for the
clinical trial will benefit, not when it conveniently becomes apparent
after the conclusion of the research that the subjects will not be able to
afford the treatment. If the decision that Africans will benefit from
the results of the research is not made prior to the selection of re
search subjects and countries, then what is the purpose for the re
search other than exploitation?114
Furthermore, in an article supportive of the AZT drug trials, the
CDC and NIH, the institutions funding some of the drug trials con
ducted in Africa, responded to these ethical questions by stating that
Justice does not simply require that popUlations participating in
107. Full issues of the New England Journal of Medicin e, the Ameiican Journal of Public
Health , and the Hastings Center Report were devoted to this topic. See generally 337 N E W E NG .
J. MED. 1 (1997); 88 AM. 1. PUB. HEALTH 1 (1998); 28 HASTINGS C ENTER REP. 1 (1998).
108. Angell, supra note 77, at 1083.
109. ld.; Angell , supra note 23, at 847-48.
110. Bayer, supra note 21, at 570.
111. Id.
112. The Belmont Report, 44 Fed. Reg. 23,192, 23,197 (Apr. 18, J 979).
113. ld. at 23,196-97.
114. Lurie & Wolfe!, supra note 24, at 854-55; Annas & Grodin, supra nute 23 at 560-61; An
geli, supra note 23, at 847-48.
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clinical trials benefit from the results but also that developing coun
tries have "equitable access to clinical trials. "115 According to the for
mer Surgeon General and the former director of the NIH, Justice
requires that vulnerable populations be allowed to participate in
clinical trials without being barred by the unavailability of the result
ing treatment. 116 Hence, it is unjust if researchers do not conduct
clinical trials in developing countries because it limits the ability of
Africans to benefit from the trials.! 17
This viewpoint alludes to the theory of fair opportunity espoused by
Norman Daniels. That theory states that everyone should have a fair
opportunity to resources, such as healthcare. 118 Fair opportunity is a
precept of Justice; however, fair opportunity without fair or equal dis
tri bution of benefits is unjust. Mere access to clinical trials without
providing access to trials that benefit developing countries under
mines the very principle of Justice stated in the Belmont Report and
the Declaration of Helsinki. The Belmont Report states that Justice
demands that researchers conducting clinical trials do not "unduly in
volve persons from groups unlikely to be among the beneficiaries of
subsequent applications of the research"; otherwise, the groups will be
exploited because they are easily accessible.!19 So, even if fairness re
quires equal access to clinical trials, these trials are not just unless a
benefit is given to the population.
This statement regarding fair access to participation in clinical trials
is further misguided because it focuses on the benefits of individual
citizens, rather than on the benefits to the population, which the Jus
tice principle addresses. Justice is defined in terms of protection of
the population not just protection of the individual participating in the
research trial. 120 In fact, the Belmont Report and the Declaration of
Helsinki state that it is not enough for the participants of the clinical
trials to be offered a benefit from the research; the population from
which the subjects are a part must actually benefit. 121 Thus, Justice
requires researchers to select populations to use as subjects in clinical
trials based on the populations' ability to benefit from the research. If
115.

Varmu~

& Saieher, supra note 25, at 1003.

116. [d.
117 [d.

118 DANIELS, supra note 37, at 34-58.
119. The Belmont Report, 44 Fed. Reg. 23,192, 23,194 (Apr. 18, 1979).
120. In the Belmont Report, the protections of individuals participating in clinical trials are
addressed by Respect for Persons and Beneficence. [d. at 23,192-96. These principles focus on
ensuring that the subjects' choices are voluntary (Respect for Persons) and that subjects are not
sacrificed for the benefit of society (Beneficence). Id. at 23,192. For a full definition of each
pri nCiple, see supru noks 9 and 10.
l21. Th e Belmont Report, 44 Fed. Reg. 23,192, 23,196 (Apr. 18, 1979).
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the popUlation will nC't benefit from the results of the research then,
according to the Belmont Report and Declaration of Helsinki, it IS
neither justifiable nor ethical to use it for the benefit of others.122
Many of the African HIV drug trials funded and conducted by the
United States were abruptly halted because of pressures placed on
researchers and funding agencies to conform to the ethical standards
used in the United States. J23 Accordingly, these actions suggest that
U.S. researchers from developed nations recognize the Justice princi
ple's requirement in selecting research subjects from populations
based on who will benefit fro m the results of the studies. To evaluate
whether clinical researchers are currently abiding by the dictates of
Justice , one can review the current HIV vaccine trials being conducted
in Africa .
IV.

HIV VACCINE TRIALS IN AFRICA: ARE THE TRIALS

A.

U~]UST?

The Structure of Clinical HIV Vaccine Trials

The purpose of clinical HIV vaccine trials is to develop a vaccine
that will either prevent the disease. as in the case of the smallpox vac
cine, or slow the progression of the disease, as in the case of the flu
vaccine. 124 To develop an effective HIV vaccine through clinical tn
als, researchers must complete three phasesY''; Phase I is conducted
using a small number of subjects, usually less than fifty people, to ob
tain information regarding the safety and effect of the candidate vac
cine on human suhjects. 126 Information regarding the immune
system's response to the vaccine, the effect of the vaccine on different
populations, and the effect of different doses on the population is
gathered from several hundred subjects in Phase II trials. 127 Phase III,
the final phase of vaccine clinical trials before the vaccine is patented
or discarded, is used by researchers to determine the efficacy of the
vaccine for preventing the disease by following several thousand sub
122. [d. at 23,197; see also WORL D M E D. ASS'N, supra note 13.
123. Varmus & Satcher, supra note 25, at 1004.
124. There an; many types of HIV vaccines being tested , but they can be separated int() tW()
main categories: prophylactic and therapeutic. See Peter Lurie e t a!., Ethical, Behavioral, and
Social Aspects of HIV Vaccine Trials in Developing Counlries, 26 JAMA 295, 295 (1994). Pro·
phylactic vaccines were developed to pre vent HIV infection , while therapeutic vaccines delay or
prevent the progression of HIV to A IDS. Id. Th e difference in purpose of the vaccin e being
tested ca n also raise additional ethical issue concerning Justice, but this topic is outside the scope
of this Article.
125 . Id. at 297; Esparza, supra no te 3, at 1133.
126. Id.
127. Id.

2004]

GOOD ENOUGH TO USE FOR RESEA RCH

1145

jects. 128 Under each phase of the trials, subjects are given a number of
vaccine doses and then tested for HIV several months later. 129
In 1987, the first Phase I clinical trial for the HIV vaccine was con
ducted in Z aire.l3O Since 1987, sixty Phase I and II trials have been
conducted, testing more than thirty candidate HIV vaccines. 131 Most
of the studies have been conducted in the United States and in Eu
rope; and Phase III trials have only been conducted in the United
States and Thailand, not in Africa,l32 This is important because only
Phase III trials provide information concerning the effectiveness of
the HIV vaccine to prevent HIV infection,133 Currently, researchers
are conducting three Phase I HIV vaccine trials in the African coun
tries of Botswana, South A frica, and Uganda,134 The U.S. govern
ment funded the Botswana and South Africa HIV vaccine trials, while
the IAVp35 funded the Uganda trials,136 Because these trials com
menced in 2003, it is hard to determine whether the results of the
study will benefit Africans. A review of these three vaccine trials
shows some improvements from the A ZT clinical trials but still raises
questions regarding what "society" will benefit from the trials. The
main question is whe ther a successful H IV vaccine will be accessible
to Africans.

B.

Issues Concerning Current HIV Clinical Vaccine Trials 137

The benefit to African society for participating in the three HIV
vaccine trials is actual access to a vaccine that will prevent new HIV
128. Id.
129. Lurie et aI., supra no~e 124, at 298.
130. Little is known about the first trial other than the fact that Dr. Zagury. who conducted
the trial, did so in Zaire because of the easy accessibility of research subjects, seemingly a viola
tion of the ethical principle of Justice. See Christakis, supra not<.: 27. at 31.
131. Esparza, supra note 3, at 1133.
132. ld.
133. [d.
134. The trials in South Africa and Botswana began "ecruiting palients in 2003 while the
Ugandan trial has been underway since February 2003. See Int'l AIDS Vaccine hitiative, FOCLI ,~
on Developing Countries, at http://www.iavi.orglvaccinedev/developing.htm(la <.tvisited Apr. 22,
2004) ; see also Nat'l Inst. of Health, Safety of an l-llV Va ccine (AVX IOI) in HIV Uninfected
Volunteers in the United Slates and South Africa (2003), at http://www.C\inicaltriab.gov/ct/show/
NCT00063778?order=q (last visited Feb. 4, 2004) [hereinafter Na t'! Inst. of Health. AVXIOI];
Nat 'l Inst. of Health, Safety of and Immune System Response to an HIV Vaccine (EP HIV-IOOO)
in HIV Uninfected Adults (2003). at http://www.clinicaltrials.gov/ct/showINCT000548b6?order=2
(last visited Feb. 4, 2004) [hereinafter Nat'l Inst. of Health, EP HIV-I090].
135. IAVI is an international nonprofit organization that is headquartered ifl the United
States. For more information, see supra subpart III(B).
136. See sources cited supra note 134.
137. There is some dispute when, and in what country, the first HIV vaccine trial was
conducted based on the most prevalent types found in Africa. There are two sources that
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infections or decrease the number of deaths from AIDS.l38 Develop
ing an effective vaccine for Africans is complicated because individual
Africans are infected with different types and strains of HIV between
themselves and a different type and strain of HIV than with which
Americans are infected.1 39 The discussion of the specific differences
in types and strains of HIV is beyond the scope of this Article; how
ever, it is because of this diversity in types and strains of infections
that many researchers believe that a vaccine, which prevents one type
of HIV infection, will not be efficacious in preventing infection by an
other strain.1 40 Instead, researchers will probably need to develop a
different HIV vaccine to prevent each of the major types and strains
of HIV.141 This problem has been addressed in each of the vaccine
trials conducted in Africa. 142 In the Botswana trial. researchers are
using a vaccine based on a combmation of the infection most preva
lent in the United States and in Africa. 143 In the trials in South Africa
and Uganda, researchers are using an HIV vaccine based on the most
prevalent type of infection in that region. 144 Yet, it is still questiona
ble whether Africans will benefit from any of these studies because of
the limited monetary resources available to pay for a vaccine.l 45
suggest that the first trial started in Kenya in 2001. See In!'1. AIDS Vaccine Initiative, supra note
134; AIDS.Org, First Vaccine for Africa Begins Trials (Jan. 26, 2001), at http://www.aids.orglatn/
a-359-02.html (last visited Nov. 5,2003). Susan Mayor, AIDS Vaccine Trial Begins in Uganda,
326 BRITISH MLD. 1. 414 (2003). The literature is also unclear on whether the Kenya study has
been concluded. See Int'l AIDS Vaccine Initiative, supra note 134. Thus, this trial will not be
discussed in further detail in this Article .
138. The difference in benefit depends on what type of HIV vaccine i~. being tested. If a
prophylactic vaccine is effective, it would prevent HIV infection after exposure, while a thera
peutic vaccine would only slow the progression of HIV to AIDS. See Lurie & Wolfe , supra note
24, at 854-55. Further discussion of the consequence of developing different types of vaccines for
use in the United States is beyond the scope of this Article; however, the author is in the process
of drafting an article to discuss the burdens and benefits of the different types of vaccines in
respect to the Justice principle.
139. Esparza, supra note 3, at 1133.
140. Id.; Lurie et aI., supm note 124, at 297.
141 . ld.
142. See Press Release , First HIV Vaccine Trial Commences in South Africa (Nov. 3, 2003),
available at http://www.mrc.ac.za/pressreleases/2003/37pres2003.htm (last visited Feb. 4, 2004);
see also Mugerwa et aI., supra note 30, at 228.
143. See Jenny Badner, Botswana & Harvard: Teaming Up To Find an AIDS Vaccine, Voice of
America, available a/ 2003 WL 59719040.
144. ld.
145. Even before HIV vaccine trials were launched in Africa, there was speculation from
many U.S. physicians and ethicists regarding the lack of HIV vaccine trials based on the types of
infection most prevalent to Africa. Dr. Peter Lurie, an American researcher and ethicist, '.tated
that it was important that vaccine trials included strains from Africa because the majority of HIV
infections were located in Africa. See Lurie et aI. , supra note 124, at 297. Additionally, Dr.
Lurie suggested that trial sites of HIV vaccine clinical trials be located in different developing
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The Botswana trial is conducted by the HIV Vaccine Trial Net
work,146 the medical schools of Harvard University in Boston and St.
Louis University in St. Louis, and funded by the NIH. The HIV trials
in Botswana are using the same vaccine currently being tested in trials
in Boston and St. Louis. Because these trials are being conducted in
the United States and in Africa, positive results from the trials pro
mote the possibility that a multinational vaccine, which would benefit
a broader society, would be developed. However, the possible bene
fits also create ethical dilemmas. There is no guarantee that the com
pany manufacturing the vaccine will price it at a level affordable for
the Botswana population. Instead, the company could simply decide
to sell the vaccine to Botswana and the United States at a price afford
able for the United States. Arguably, this would make the vaccine
accessible to the population of Botswana. Notwithstanding this access,
no one in Botswana would be able to afford to buy the vaccine, and
therefore, the Botswana population would not realize the benefits of
the research trial.
To address this issue of access, the researchers from Harvard Uni
versity are currently conducting studies in Botswana to create health
infrastructures to treat HIV infection and a fellowship program to
train scientists to conduct research in developing countries, such as
Botswana. But, this neither addresses the issue of afford ability of the
vaccine nor guarantees that the citizens of Botswana will realize the
benefits of the trial: access to the vaccine if it proves effective. The
failure of Africans to realize the benefits of clinical trials is not an
uncommon occurrence. This is what happened in the AZT drug trials
conducted in the 1990s in the United States and Africa. Although the
results of those trials, a shorter-length treatment of AZT, were of
fered to both the United States and Africa, only the United States
could afford to provide the treatment to its citizens.147 Thus, those
trials violated the Justice principle, as espoused in the Belmont Re
port, because Africans bore the burden but failed to receive the bene
fit from the trials. As in the case of those trials, if the Botswana trial
nations such as in Africa, otherwise the vaccine will disproportionately benefit one population
while shouldering the burdens with others. Id.
146. In 1999, the HIV Vaccine Trial Network was formed by the Division of AIDS of the
National Institute of Allergy and Infectious Diseases (NIAID), a component of the National
Institutes of Ht:alth (NIH), when the federal government reorganized. See About the HIV Vac
cine Trial Network (2003), at http://www.hvtn.orglabout (last visited Feb. 4, 2004). Since that
time the HIV Vaccine Trial Network has blossomed into an international organization dedicated
to conducting international HIV vaccine trials composed of twenty-seven research institutions
worldwide and headquartered at the Fred Hutchinson Cancer Rest:arch Center. ld.
147. Lurie & Wolfe, supra note 24, at 854-55.
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fails to provide an actual benefit to the population of Botswana, the
trial would violate the Belmont Report's Justice principle, because the
"society" bearing part of the burden, the Botswana popUlation, would
receive none of the benefits of the research. This is also a problem in
the South African HIV vaccine trial.
The South African trial is being conducted by the HIV Vaccine Trial
Network and funded by the NIH in conjunction with the Medical Re
search Council for South Africa (MRC). Testing has recently begun ,
but there is no mention in the literature whether the vaccine, if effec
tive, will be accessible to the population of South Africa.148 The
MRC's guidelines on ethics in medical research state that any result
from research supported by MRC vests rights in MRC to patent the
product of the research. H9 However, the guidelines also allow fi nan
cial sponsors to have full rights to the results of the research, making
the HIV Vaccine Trial Network or NIH or both , the owners of the
vaccine patent.1 so Without further information, it is impossible to de
termine whether the trials will provide a benefit to the South African
population that it is testing. The past has shown, however, that after
studies are concluded there is no guarantee that African society will
have actual access to the treatment tested. Thus, the failure of the
HIV Vaccine Trial Network or the NIH to pledge access to the vaccine
if it proves effective in either the Botswana or South African trial
leaves the door open for violations of the Justice principle that oc
curred in past AZT drug trials.
The Uganda trial conducted by IAVI, an international scientific,
nonprofit organization founded in 1996, seems to be the one HIV vac
cine trial most likely to produce a benefit for the African popula
tion ,lS1 Concerned with reports of vaccine researchers and
manufacturers using clinical trials in poor countries to exploit weaker
ethical protections for conducting biomedical research, the Ugandan
government negotiated an agreement with IAVI that the vaccine, if
effective, be accessible to the local population. 152 This agreement
148. See Press Release, First HIV Vaccine Trial , supra note 142.
149. GUIDELI NES ON ETHICS FOR MEDICAL R ESEARCH, OWNERSHIP OF R ESULTS: PATENT
RIGHTS, COPYRIG HT, AND CONFIDENTIALITY (1993), available at http://www.mrc.ac.za/e thics/
ownership.htm (last visited Feb. 4, 2004).
150. MED. RESEARCH COUNCIL, G UIDELI NES ON ETHICS FOR MEDICAL R ESEA RCH, OWN ER
SHIP OF R ESU LTS OF R ESEARCH (1993), available at http://www.mrc.ac.za/ethic./ownership. htm
(last visited Feb. 4, 2004) (discussing ownership rights of financial sponsors).
151. The main purpose of IAVI is to accelerate the development of safe, effective, and accessi
ble HIV vaccines globally. Page, supra note 16, at 57. To achi eve this end, IAVI provides money

for private industry to develop and test HIV vaccines and then links the industry to forei gn
countries for testing. [d .
152. Mugerwa et aI., supra note 30, at 228.
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seemingly ensures that Ugandans wili benefit from the results of the
vaccine trials, but what is "accessible '''! Uganda does not have the
intellectual property rights to the vaccine, the infrastructure to admin
ister the vaccine, or the right to manufacture the vaccine. l53 Thus, the
same problem that arose in Uganda in 1997 during the AZT drug trial
studies could reoccur. In 1997, Uganda only spent ten dollars per pa
tient per year on health care; thus, they could ill afford to provide the
shorter length AZT treatment at sixty dollars per patient to pregnant
women to prevent perinatal HIY transmissionP4 If the vaccine is
more than what Uganda currently spends per patient per year, then
Ugandans may not actually have access to a vaccine, and the trials will
be unjust. 155

C.

Solution to Promote Justice in All International Clinical Trials

Both the South African and the Ugandan HIY vaccine trials pose a
new quandary for ethicists: how to regulate clinical trials funded and
conducted by different countries or private companies. Neither trial
would exclusively fall under the realm of the Belmont Report because
the U.S. government does not wholly fund the research. The Declara
tion of Helsinki could be used to regulate the researchers conducting
the trials, because each of the studies is conducted in part by foreign
entities, thus triggering international law; however, the Declaration of
Helsinki is only advisory. To rectify this problem, some scholars have
suggested the use of prior agreements between foreign countries and
researchers regarding the benefits of the research as the best way to
address the ethical requirements of Justice; however, prior agreements
pose the same problem as using the Declaration of Helsinki-there is
no enforcement mechanism.l 56
As discussed above, IAYI and Uganda entered into a prior agree
ment regarding the accessibility of an effective HIY vaccine. Al
though the agreement between Uganda and IAYI purports to ensure
that Ugandans have access to an effective vaccine, Uganda does not
153. [d.
154. Annas & Grodin, supra note 23, at 564. Currently, Uganda only spends $6 per year per
patie nt , while the United States spends approximately $5,775 per patient. See VlUgerwa et aI.,
supra note 30, at 228; see also OFFICE OF THE A CTUARY , supra note 103.
155. Uganda does have its own ethical requireme nts, but the requirements reiating to the
Justice principle are advisory. The U ganda National Consensus Conference Guidelines for the
Conduct of Health Research Involv ing Human Subjects in Uganda requires a researcher only
make a reasonable effort to secure the product's availability to the local community in which the
research occurred. See NATIOt;AL CONFERENCE, GU IDELI NES FO R THE CONDUCT OF H EALTH
R ESEA RCH INVOLVI NG HC\1A I' SUBJ ECTS IN U GANDA § V(D)(4) (1997), cited in Page, supra
note 16, at 51 n.58.
156. Page, supra note 16.
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have any more enforceable mechanism to challenge the manufacturer
than it did under the Declaration of Helsinki. IAVI has implemented
a number of legally enforceable contractual measures including trans
ferring the rights to produce the vaccine to another manufacturer if
the manufacturer is unwilling to provide the HIV vaccine at a price
that Uganda can afford, but this legally enforceable remedy is not
available to U ganda. 157 IAVI retains all rights and powers to the pro
duction of the vaccine. Therefore, lAVI, a private organization, can
decide whether or not to enforce its contracts with private manufac
turers for the benefit of Uganda. If IAVI decides not to enforce the
provision, Ugandans will not receive any benefit from the results of
the trials.
Another possible solution to prevent the continued exploitation of
Africans and the perversion of the Justice requirement is the creation
of an international compulsory standard of ethical protections of
human subjects participating in clinical trials. The standards would be
drafted, implemented, and enforced by one international body. The
United Nations Programme on HIV and AIDS has become the pre
mier international organization in terms of HIV and AIDS research
and would be the best place for this newly formed international regu
latory body. For the organization to be effective, the standards must
have penalties if they are violated, and the organization must have
some ability to enforce their decisions. The organization's ability to
enforce this standard will be subject to the structure of its governing
document and the membership of the organization. If the document
mirrors some of the current standards already compulsory in the
United States under the Belmont Report and already agreed to by
many medical professionals under the Declaration of Helsinki, then
more countries will opt to comply because it will not challenge the
status quo. Furthermore, if the membership of the organization in
cludes the United States and key members of the European Union,
researchers from those countries will comply with the dictates of the
organiza tion.
However, membership to the organization must be balanced to in
clude many of the developing countries being exploited. To be fair in
combating ethical violations in developing countries , the membership
of the organization must be proportionate to the amount of research
conducted in a country by researchers from other countries. With the
creation of this compulsory international statement of ethics and en
forcement, researchers and private funders will be held accountable
157. ld. at 59.
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for their ethical violations and deterred from committing the violation
again, thus protecting vulnerable populations from exploitation. Pri
vate funders and pharmaceutical companies may try to argue that
their research is private and not subject to the mandates of an interna
tional organization; however, researchers from member countries will
be required to follow the dictates of the organization, and, thus, their
funders must comply in order to conduct research in developing na
tions. This is the best way to ensure that Africans are not exploited
for the benefit of other populations, because it empowers the ex
ploited society to protect its own citizens through enforceable means,
rather than leaving them to rely on the mercy of a private entity.
V.

CONCLUSION

The large number of persons infected with HIV in Africa combined
with the inadequate monetary resources for purchasing medications to
treat HIV-infected persons makes Africa ideal for conducting HIV
vaccine trials.158 However, in light of the recent history of the AZT
drug trials in which Africans were exploited,159 Africans were con
cerned about reports in the foreign media that manufacturers might
choose to test vaccines in poor countries to reduce product liability in
case of injury or to exploit weaker legal, ethical, or regulatory mecha
nisms for conducting biomedical research.1 60 In fact, many Africans
"asked whether the [HIV vaccine] trial was an example of 'hit and run
research' by scientists from rich countries, in which a poor country
was chosen as the setting because the study would be cheaper and
fewer questions would be asked about safety and ethics."lul As
clinical HIV vaccine trials commence, Africans wonder if they will re
ceive any benefit as a society from the research or will simply be
exploitcd. 162
In the past, there has been much discussion regarding the require
ment of providing a benefit to an African society after conducting an
HIV clinical trial in Africa. 163 Some have lauded the research com
lSi':. Id.
159. An example of exploitation of Africans used in clinical trials was the 1990 AZT drug
trial s. For more information, see supra subpart II(B).
160. ld.
161. See Mugerwa et at , supra note 30, at 228.
162. rd.
163. See generally id.; David Orentlicher, Univ ersality and Its Limits: When Research Ethics
Can Reflect Local Circumstances, 30 J.L. MED . & ETJ-Hes 403 (2002); Joanne Roman, Note, us.
Medical Research in the Developing World: Ignoring Nuremberg, 11 CORNELL J.L & Pt ~fl. POt 'y
441 (2002).
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munity for giving Africans equitable access to clinical trials,164 but
mere access to trials without any guarantee that the results of the tri
als will provide a benefit to Africans leaves them with the burden but
no benefit. Both the Belmont Report and the Declaration of Helsinki
require that the population studied receive a benefit to ensure that
populations are not exploited or used in trials for the benefit of
others. 165 In the current H IV vaccine trials, the very structure of
clinical trials would negate any significant benefits individual Africans
would receive from participating in clinical trials. Because these
Phase I clinical trials are merely evaluating the safety of the vaccine
versus the dangers and side effects of the vaccine, the net benefit from
the trials is to the society that gains access to an effective vaccine after
Phase III trials, not the participants in the clinical trials.
Therefore, rather than focusing on mere access to trials, there is a
need for researchers to shift their thinking and perception of the bene
fits of clinical trials in Africa. The key to this shift is to focus on the
fact that the benefit researchers are trying to obtain is for society. So
ciety includes all countries but specifically the country researchers
used for the research. Thus, as researchers choose research subjects
for HIV vaccine trials in Africa , they should make the choice based on
the view that research is conducted to save human lives, which in
cludes the lives of the people in the country where clinical trials are
conducted. Simply viewing these subjects as dispensable figures ne
glects not only the spirit of the research subject protocol rules but also
violates the letter of the rule. The Belmont Report and the Declara
tion of Helsinki require that the population benefit from the research,
not simply that the researchers offer the population a benefit; other
wise, the research is not justified.1 66 Unfortunately, the Belmont Re
port and the Declaration of Helsinki do not protect all research
subjects. The Belmont Report is only compulsory for research funded
by the United States, while the Declaration of Helsinki is only a guide
to researchers.
To prevent this gap in protection, some scholars have suggested pro
moting prior agreements between the researchers, funde rs, and the
foreign country.1 67 H owever, these agreements are not always en
forceable and can lead to different outcomes for different countries
based on the power base of the country negotiating the deal. A better

M

164. Varmus & Satcher, sup ra note 25 , at 1004.
165. The Belmont Report , 44 Fed. Reg. 23,192, 23,196-97 (Apr. 18, 1979); see also
E D. ASS'N, supra note 13.
166. The Belmont Report, 44 Fed. Reg. at 23,194.
167. Page, supra note 16.
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way to prevent the continued exploitation of Africans is to create an
international compulsory standard of ethical protections of human
subjects participating in clinical trials enforced by an international
body whose membership includes representatives from developing
countries. With the creation of this compulsory international state
ment of ethics and enforcement organization, researchers will be held
accountable for their ethical violations in developing countries, which
would deter them from committing the violations again and would
protect vulnerable populations from exploitation.

